Use of statin therapy to reduce cardiovascular risk in older patients

Current Gerontology and Geriatrics Research

Volumn 2010, Issue , 2010, Pages

  Wenger, N K ^a   Lewis, S J ^b  

^a EMORY UNIVERSITY   (United States)

^b Northwest Cardiovascular Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78349294960     PISSN: 16877063     EISSN: 16877071     Source Type: Journal    
DOI: 10.1155/2010/915296     Document Type: Review

References (62)

1. Lloyd-Jones D., Adams R., Carnethon M., Heart disease and stroke statistics2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 2009 119 3 e21 e181
2. Kung H. C., Hoyert D. L., Xu J., Murphy S. L., Deaths: final data for 2005 National Vital Statistics Reports 2008 56 10 1 120
3. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report Circulation 2002 106 25 3143 3421
4. Grundy S. M., Cleeman J. I., Merz C. N., Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 2004 110 2 227 239
5. Anderson J. L., Adams C. D., Antman E. M., ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine Journal of the American College of Cardiology 2007 50 e1 e157
6. Fraker T. D. Jr., Fihn S. D., 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines writing group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina Journal of the American College of Cardiology 2007 50 23 2264 2274
7. Pan H. Y., Waclawski A. P., Funke P. T., Whigan D., Pharmacokinetics of pravastatin in elderly versus young men and women Annals of Pharmacotherapy 1993 27 9 1029 1033
8. Gibson D. M., Bron N. J., Richens A., Hounslow N. J., Sedman A. J., Whitfield L. R., Effect of age and gender on pharmacokinetics of atorvastatin in humans Journal of Clinical Pharmacology 1996 36 3 242 246
9. Martin P. D., Dane A. L., Nwose O. M., Schneck D. W., Warwick M. J., No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor Journal of Clinical Pharmacology 2002 42 10 1116 1121
10. Pedersen T. R., Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994 344 8934 1383 1389
11. Sacks F. M., Pfeffer M. A., Moye L. A., The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels The New England Journal of Medicine 1996 335 14 1001 1009
12. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group The New England Journal of Medicine 1998 339 1349 1357
13. Lewis S. J., Moye L. A., Sacks F. M., Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the cholesterol and recurrent events (CARE) trial Annals of Internal Medicine 1998 129 9 681 689
14. Hunt D., Young P., Simes J., Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial Annals of Internal Medicine 2001 134 10 931 940
15. Miettinen T. A., Pyorala K., Olsson A. G., Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S) Circulation 1997 96 12 4211 4218
16. Lemaitre R. N., Psaty B. M., Heckbert S. R., Kronmal R. A., Newman A. B., Burke G. L., Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the cardiovascular health study Archives of Internal Medicine 2002 162 12 1395 1400
17. Collins R., Armitage J., Parish S., Sleight P., Peto R., MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial Lancet 2002 360 9326 7 22 (Pubitemid 34756487)
18. Sever P. S., Dahlof B., Poulter N. R., Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes TrialLipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 2003 361 9364 1149 1158 (Pubitemid 36398384)
19. Shepherd J., Blauw G. J., Murphy M. B., Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 2002 360 9346 1623 1630
20. Afilalo J., Duque G., Steele R., Jukema J. W., de Craen A. J. M., Eisenberg M. J., Statins for secondary prevention in elderly patients. A hierarchical Bayesian meta-analysis Journal of the American College of Cardiology 2008 51 1 37 45
21. Brugts J. J., Yetgin T., Hoeks S. E., The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials British Medical Journal 2009 338 b2376
22. Wenger N. K., Lewis S. J., Herrington D. M., Bittner V., Welty F. K., Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease Annals of Internal Medicine 2007 147 1 1 9
23. Koren M. J., Feldman T., Mendes R. A., Impact of high-dose atorvastatin in coronary heart disease patients age 65 to 78 years Clinical Cardiology 2009 32 5 256 263
24. Deedwania P., Stone P. H., Merz C. N. B., Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE) Circulation 2007 115 6 700 707
25. Massing M. W., Sueta C. A., Chowdhury M., Biggs D. P., Simpson R. J., Lipid management among coronary artery disease patients with diabetes mellitus or advanced age American Journal of Cardiology 2001 87 5 646 649
26. Nichols G. A., Nag S., Chan W., Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update American Heart Journal 2007 154 554 560
27. Grundy S. M., Pasternak R., Greenland P., Smith S., Fuster V., Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology Journal of the American College of Cardiology 1999 34 4 1348 1359 (Pubitemid 29500569)
28. Junyent M., Zambon D., Gilabert R., Carotid atherosclerosis and vascular age in the assessment of coronary heart disease risk beyond the Framingham Risk Score Atherosclerosis 2008 196 2 803 809
29. Kannel W. B., D'Agostino R. B., The importance of cardiovascular risk factors in the elderly American Journal of Geriatric Cardiology 1995 4 2 10 23
30. de Lemos J. A., Blazing M. A., Wiviott S. D., Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial Journal of the American Medical Association 2004 292 11 1307 1316
31. Link E., Parish S., Armitage J., SLCO1B1 variants and statin-induced myopathya genomewide study The New England Journal of Medicine 2008 359 8 789 799
32. Alexander K. P., Blazing M. A., Rosenson R. S., Management of hyperlipidemia in older adults Journal of Cardiovascular Pharmacology and Therapeutics 2009 14 1 49 58
33. Cannon C. P., Braunwald E., McCabe C. H., Intensive versus moderate lipid lowering with statins after acute coronary syndromes The New England Journal of Medicine 2004 350 15 1495 1504
34. Schwartz G. G., Olsson A. G., Ezekowitz M. D., Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial Journal of the American Medical Association 2001 285 13 1711 1718
35. Ray K. K., Bach R. G., Cannon C. P., Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS European Heart Journal 2006 27 19 2310 2316
36. Olsson A. G., Schwartz G. G., Szarek M., Luo D., Jamieson M. J., Effects of high-dose atorvastatin in patients ≥65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study) American Journal of Cardiology 2007 99 5 632 635
37. Wenger N. K., LaRosa J., Shepherd J., High-dose atorvastatin provides sustained benefit in reducing risk of cardiovascular disease among stable coronary heart disease patients 65 years of age or older Proceedings of the American College of Cardiology 58th Annual Scientific Session 2009 Orlando, Fla, USA
38. Alberti K. G., Zimmet P., Shaw J., Metabolic syndromea new world-wide definition. A consensus statement from the International Diabetes Federation Diabetic Medicine 2006 23 5 469 480
39. Shepherd J., Barter P., Carmena R., Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the treating to new targets (TNT) study Diabetes Care 2006 29 6 1220 1226
40. Shepherd J., Kastelein J. J., Bittner V., Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease. The TNT (Treating to New Targets) study Journal of the American College of Cardiology 2008 51 15 1448 1454 (Pubitemid 351471787)
41. Shepherd J., Kastelein J. J., Bittner V. A., Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease Mayo Clinic Proceedings 2008 83 8 870 879
42. Ridker P. M., Danielson E., Fonseca F. A., Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein The New England Journal of Medicine 2008 359 21 2195 2207
43. Dahlof B., Sever P. S., Poulter N. R., Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial Lancet 2005 366 9489 895 906
44. Collier D. J., Poulter N. R., Dalhof B., Impact of atorvastatin on cardiovascular events in 2440 men and women aged 65 years and above: evidence from the Anglo-Scandinavian outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) Stroke 2006 37 692
45. LaRosa J. C., Grundy S. M., Waters D. D., Intensive lipid lowering with atorvastatin in patients with stable coronary disease The New England Journal of Medicine 2005 352 14 1425 1435
46. Tikkanen M. J., Holme I., Cater N. B., Comparison of efficacy and safety of atorvastatin (80mg) to simvastatin (20 to 40mg) in patients aged 65 Versus ≥65 years with coronary heart disease (from the incremental decrease through aggressive lipid lowering [IDEAL] study) American Journal of Cardiology 2009 103 5 577 582
47. Hey-Hadavi J. H., Kuntze E., Luo D., Silverman P., Pittman D., LePetri B., Tolerability of atorvastatin in a population aged ≥65 years: a retrospective pooled analysis of results from fifty randomized clinical trials American Journal of Geriatric Pharmacotherapy 2006 4 2 112 122
48. Hey-Hadavi J., Laskey R., Breazna A., Atorvastatin safety in patients 75 years and older Proceedings of the 16th International Symposium on Drugs Affecting Lipid Metabolism 2007 New York, NY, USA
49. Alsheikh-Ali A. A., Karas R. H., Adverse events with concomitant amiodarone and statin therapy Preventive Cardiology 2005 8 2 95 97
50. Neuvonen P. J., Niemi M., Backman J. T., Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance Clinical Pharmacology and Therapeutics 2006 80 6 565 581
51. Davidson M. H., Robinson J. G., Safety of aggressive lipid management Journal of the American College of Cardiology 2007 49 17 1753 1762
52. Westergren T., Johansson P., Molden E., Probable warfarin-simvastatin interaction Annals of Pharmacotherapy 2007 41 7-8 1292 1295
53. Stern R., Abel R., Gibson G. L., Besserer J., Atorvastatin does not alter the anticoagulant activity of warfarin Journal of Clinical Pharmacology 1997 37 11 1062 1064
54. Davidson M. H., Armani A., McKenney J. M., Jacobson T. A., Safety considerations with fibrate therapy American Journal of Cardiology 2007 99 6 3C 18C
55. Kane G. C., Lipsky J. J., Drug-grapefruit juice interactions Mayo Clinic Proceedings 2000 75 9 933 942
56. Sugimoto K., Ohmori M., Tsuruoka S., Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin Clinical Pharmacology and Therapeutics 2001 70 6 518 524
57. Foody J. M., Joyce A. T., Rudolph A. E., Liu L. Z., Benner J. S., Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study Current Medical Research and Opinion 2008 24 7 1987 2000
58. Benner J. S., Glynn R. J., Mogun H., Neumann P. J., Weinstein M. C., Avorn J., Long-term persistence in use of statin therapy in elderly patients Journal of the American Medical Association 2002 288 4 455 461
59. Jackevicius C. A., Mamdani M., Tu J. V., Adherence with statin therapy in elderly patients with and without acute coronary syndromes Journal of the American Medical Association 2002 288 4 462 467
60. Benner J. S., Pollack M. F., Smith T. W., Bullano M. F., Willey V. J., Williams S. A., Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy American Journal of Health-System Pharmacy 2005 62 14 1468 1475
61. Parris E. S., Lawrence D. B., Mohn L. A., Long L. B., Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia Diabetes Care 2005 28 3 595 599
62. Schultz J. S., O'Donnell J. C., McDonough K. L., Sasane R., Meyer J., Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population American Journal of Managed Care 2005 11 5 306 312